These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 10201369)

  • 1. Molecular basis of triclosan activity.
    Levy CW; Roujeinikova A; Sedelnikova S; Baker PJ; Stuitje AR; Slabas AR; Rice DW; Rafferty JB
    Nature; 1999 Apr; 398(6726):383-4. PubMed ID: 10201369
    [No Abstract]   [Full Text] [Related]  

  • 2. Triclosan targets lipid synthesis.
    McMurry LM; Oethinger M; Levy SB
    Nature; 1998 Aug; 394(6693):531-2. PubMed ID: 9707111
    [No Abstract]   [Full Text] [Related]  

  • 3. Structural basis and mechanism of enoyl reductase inhibition by triclosan.
    Stewart MJ; Parikh S; Xiao G; Tonge PJ; Kisker C
    J Mol Biol; 1999 Jul; 290(4):859-65. PubMed ID: 10398587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystallographic analysis of triclosan bound to enoyl reductase.
    Roujeinikova A; Levy CW; Rowsell S; Sedelnikova S; Baker PJ; Minshull CA; Mistry A; Colls JG; Camble R; Stuitje AR; Slabas AR; Rafferty JB; Pauptit RA; Viner R; Rice DW
    J Mol Biol; 1999 Nov; 294(2):527-35. PubMed ID: 10610777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis for triclosan activity involves a flipping loop in the active site.
    Qiu X; Janson CA; Court RI; Smyth MG; Payne DJ; Abdel-Meguid SS
    Protein Sci; 1999 Nov; 8(11):2529-32. PubMed ID: 10595560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A triclosan-resistant bacterial enzyme.
    Heath RJ; Rock CO
    Nature; 2000 Jul; 406(6792):145-6. PubMed ID: 10910344
    [No Abstract]   [Full Text] [Related]  

  • 7. Structural insights into Staphylococcus aureus enoyl-ACP reductase (FabI), in complex with NADP and triclosan.
    Priyadarshi A; Kim EE; Hwang KY
    Proteins; 2010 Feb; 78(2):480-6. PubMed ID: 19768684
    [No Abstract]   [Full Text] [Related]  

  • 8. X-ray crystallographic analysis of the complexes of enoyl acyl carrier protein reductase of Plasmodium falciparum with triclosan variants to elucidate the importance of different functional groups in enzyme inhibition.
    Maity K; Bhargav SP; Sankaran B; Surolia N; Surolia A; Suguna K
    IUBMB Life; 2010 Jun; 62(6):467-76. PubMed ID: 20503440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase.
    Levy CW; Baldock C; Wallace AJ; Sedelnikova S; Viner RC; Clough JM; Stuitje AR; Slabas AR; Rice DW; Rafferty JB
    J Mol Biol; 2001 May; 309(1):171-80. PubMed ID: 11491286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan.
    Ward WH; Holdgate GA; Rowsell S; McLean EG; Pauptit RA; Clayton E; Nichols WW; Colls JG; Minshull CA; Jude DA; Mistry A; Timms D; Camble R; Hales NJ; Britton CJ; Taylor IW
    Biochemistry; 1999 Sep; 38(38):12514-25. PubMed ID: 10493822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for triclosan and NAD binding to enoyl-ACP reductase of Plasmodium falciparum.
    Suguna K; Surolia A; Surolia N
    Biochem Biophys Res Commun; 2001 Apr; 283(1):224-8. PubMed ID: 11322792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effect of epigallocatechin gallate and triclosan on enoyl-ACP reductase of Mycobacterium tuberculosis.
    Sharma SK; Kumar G; Kapoor M; Surolia A
    Biochem Biophys Res Commun; 2008 Mar; 368(1):12-7. PubMed ID: 17996734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signature gene expression profile of triclosan-resistant Escherichia coli.
    Yu BJ; Kim JA; Pan JG
    J Antimicrob Chemother; 2010 Jun; 65(6):1171-7. PubMed ID: 20410062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for the variation in triclosan affinity to enoyl reductases.
    Pidugu LS; Kapoor M; Surolia N; Surolia A; Suguna K
    J Mol Biol; 2004 Oct; 343(1):147-55. PubMed ID: 15381426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic determinants of the interaction of enoyl-ACP reductase from Plasmodium falciparum with its substrates and inhibitors.
    Kapoor M; Dar MJ; Surolia A; Surolia N
    Biochem Biophys Res Commun; 2001 Dec; 289(4):832-7. PubMed ID: 11735121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.
    Seefeld MA; Miller WH; Newlander KA; Burgess WJ; Payne DJ; Rittenhouse SF; Moore TD; DeWolf WE; Keller PM; Qiu X; Janson CA; Vaidya K; Fosberry AP; Smyth MG; Jaworski DD; Slater-Radosti C; Huffman WF
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2241-4. PubMed ID: 11527706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoyl-ACP reductase (FabI) of Haemophilus influenzae: steady-state kinetic mechanism and inhibition by triclosan and hexachlorophene.
    Marcinkeviciene J; Jiang W; Kopcho LM; Locke G; Luo Y; Copeland RA
    Arch Biochem Biophys; 2001 Jun; 390(1):101-8. PubMed ID: 11368521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent antimicrobial action of triclosan-lysozyme complex against skin pathogens mediated through drug-targeted delivery mechanism.
    Hoq MI; Ibrahim HR
    Eur J Pharm Sci; 2011 Jan; 42(1-2):130-7. PubMed ID: 21078387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triclosan: a widely used biocide and its link to antibiotics.
    Schweizer HP
    FEMS Microbiol Lett; 2001 Aug; 202(1):1-7. PubMed ID: 11506900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the interaction energies for the binding of hydroxydiphenyl ethers to enoyl-acyl carrier protein reductases.
    Muralidharan J; Suguna K; Surolia A; Surolia N
    J Biomol Struct Dyn; 2003 Feb; 20(4):589-94. PubMed ID: 12529157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.